Using stem cells to treat cancers
Using stem cells to treat cancers
Global efforts are underway to understand diabetes and hypertension in large populations.
The priority disease list for 2018 from @WHO
GOP lawmakers take aim at @WHO agency supporting #cancer research over Roundup ingredient shown to be #carcinogenic
Doctors Without Borders (MSF) recently noted the one of the best products to treat deadly snakebites has ended production and the remaining supply will soon be exhausted. FAV-Afrique can be used to treat bites from ten venomous snakes, and has been a mainstay in sub-Saharan Africa. At the root of this incredible situation is the fact that Sanofi Pasteur had stopped producing FAV-Afrique years before due to cost competitiveness. The World Health Organization (WHO), MSF, and other related organizations knew of this production stoppage and advocated for transfer of IP from Sanofi to another company to continue production. Yet, this life-saving products remains shelved and would be at least a few years from replenishment even under the most ideal circumstances.
In the United States, under Health and Human Services, an organization exists whose charter is to produce late stage therapeutics -especially in therapeutic areas that Big Pharma has largely exited. In fact, Peptineo had lobbied to employ this same resource to produce a late stage Ebola vaccine that had been shelved. This process was successfully engaged for MAPP Pharmaceuticals (producers of ZMapp) to produce its Ebola antibody cocktail -and BARDA has a pipeline of other products that it is producing. Under BARDA, a virtual pharmaceutical manufacturing capability has been established to take a therapeutic into production and complete all required regulatory milestones for FDA licensure. While BARDA may not be positioned to produce this desperately needed anti-venom, the model for producing late-stage or previously approved regulatory products is worth consideration. Given that modern manufacturing of pharmaceuticals has experienced a significant reduction in infrastructure costs and physical footprints to produce products (example: NNE Pharmaplan flexible manufacturing designs), perhaps the WHO and others should consider establishing rapid manufacturing capabilities similar to BARDA. Not only can products be made, but a streamlined process has also been developed to move products quickly through necessary regulatory efforts. The following links directly to additional background on the incredible stoppage and shelving of the FAV-Afrique anti-venom and is found here
Below is an recent discussion on plans to address potential Zika transmission during the Olympic Games. Many athletes have chosen not to participate and Global preparedness continues to be a concern.
The WHO leader Margaret Chan recently spoke on the emergence of Zika and other insect-borne illnesses. She noted that opportunities stretching back to the 1970's were missed to limit the spread of insect-related illnesses. More on this story here
The United States of America is preparing for Zika to reach its shores. As it prepares, the CDC has an emergency response group working behind the scenes to anticipate and respond to this emerging health concern.
For more information on what the CDC is doing to prepare for Zika see below...
Here is a recent update on cases being reported in Brazil on Zika. The data was compiled by Brazil Ministry of Health and assembled by Ian MacKay, PhD.
C-SPAN recently televised a discussion on climate change with implications for the rise of Zika virus cases. Below is the video archive of that discussion on C-SPAN.
Here is the link to the video
Emory university, one of the first US hospitals to treat Ebola now prepares for the next health concern - Zika. Here is a video of Grand Rounds at Emory university.
Want to learn more about how to prevent Zika? This infographic from the US Centers for Disease Control may be helpful.